Journal
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY
Volume 43, Issue 3, Pages 441-447Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/03639045.2016.1258409
Keywords
Leuprolide acetate; 3-month depot; luphere 3M; lucrin; pharmacokinetics; prostate cancer patients
Categories
Ask authors/readers for more resources
A 3-month depot formulation of leuprolide acetate (Luphere 3M Depot) with a mean microsphere diameter of 22.3 mu m was prepared aseptically by spray-drying glacial acetic acid solution of the drug and polylactic acid, and lyophilization in a D-mannitol solution. The encapsulation efficiency and loading content of the drug in the Luphere 3M Depot were 94.7% and 9.92% (w/w), respectively. The in vitro release of leuprolide from the depot was substantially delayed and the release profile was similar to that of Lucrin Depot (Abbott Korea, Korea). The safety and pharmacokinetics of leuprolide were investigated over a period of 42 days in 20 prostate cancer patients following a subcutaneous injection of Luphere 3M or Lucrin Depot suspensions (leuprolide acetate dose of 11.25mg) in a multi-center, randomized, single dose, parallel study. Both formulations were well tolerated by the patients and no serious adverse effects were observed during and after the study. No significant differences were observed in the maximum serum concentration (C-max) and area under the curve (AUC(last)) of leuprolide between the two formulations. The results suggest comparable safety and efficacy profiles of Luphere 3M Depot and Lucrin Depot in clinical situations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available